In today’s evolving global world, the pharmaceutical sector faces an emerging challenge, which is the rapid surge of the global population and the consequent growth in drug production demands. Recognizing this, our study explores the urgent need to strengthen pharmaceutical production capacities, ensuring drugs are allocated and stored strategically to meet diverse regional and demographic needs. Summarizing our key findings, our research focuses on the promising area of drug demand forecasting using artificial intelligence (AI) and machine learning (ML) techniques to enhance predictions in the pharmaceutical field. Supplied with a rich dataset from Kaggle spanning 600,000 sales records from a singular pharmacy, our study embarks on a thorough exploration of univariate time series analysis. Here, we pair conventional analytical tools such as ARIMA with advanced methodologies like LSTM neural networks, all with a singular vision: refining the precision of our sales. Venturing deeper, our data underwent categorisation and were segmented into eight clusters premised on the ATC Anatomical Therapeutic Chemical (ATC) Classification System framework. This segmentation unravels the evident influence of seasonality on drug sales. The analysis not only highlights the effectiveness of machine learning models but also illuminates the remarkable success of XGBoost. This algorithm outperformed traditional models, achieving the lowest MAPE values: 17.89% for M01AB (anti-inflammatory and antirheumatic products, non-steroids, acetic acid derivatives, and related substances), 16.92% for M01AE (anti-inflammatory and antirheumatic products, non-steroids, and propionic acid derivatives), 17.98% for N02BA (analgesics, antipyretics, and anilides), and 16.05% for N02BE (analgesics, antipyretics, pyrazolones, and anilides). XGBoost further demonstrated exceptional precision with the lowest MSE scores: 28.8 for M01AB, 1518.56 for N02BE, and 350.84 for N05C (hypnotics and sedatives). Additionally, the Seasonal Naïve model recorded an MSE of 49.19 for M01AE, while the Single Exponential Smoothing model showed an MSE of 7.19 for N05B. These findings underscore the strengths derived from employing a diverse range of approaches within the forecasting series. In summary, our research accentuates the significance of leveraging machine learning techniques to derive valuable insights for pharmaceutical companies. By applying the power of these methods, companies can optimize their production, storage, distribution, and marketing practices.

Hospital fraud detection has often relied on periodic audits that miss evolving, internet-mediated patterns in electronic claims. An artificial intelligence and machine learning pipeline is being developed that is leakage-safe, imbalance aware, and aligned with operational capacity for large healthcare datasets. The preprocessing stack integrates four tables, engineers 13 features, applies imputation, categorical encoding, Power transformation, Boruta selection, and denoising autoencoder representations, with class balancing via SMOTE-ENN evaluated inside cross-validation folds. Eight algorithms are compared under a fraud-oriented composite productivity index that weighs recall, precision, MCC, F1, ROC-AUC, and G-Mean, with per-fold threshold calibration and explicit reporting of Type I and Type II errors. Multilayer perceptron attains the highest composite index, while CatBoost offers the strongest control of false positives with high accuracy. SMOTE-ENN provides limited gains once representations regularize class geometry. The calibrated scores support prepayment triage, postpayment audit, and provider-level profiling, linking alert volume to expected recovery and protecting investigator workload. Situated in the Future Internet context, this work targets internet-mediated claim flows and web-accessible provider registries. Governance procedures for drift monitoring, fairness assessment, and change control complete an internet-ready deployment path. The results indicate that disciplined preprocessing and evaluation, more than classifier choice alone, translate AI improvements into measurable economic value and sustainable fraud prevention in digital health ecosystems.

Myocardial infarction (MI) remains a leading cause of in-hospital mortality. Early identification of high-risk patients is essential for improving clinical outcomes and optimizing hospital resource allocation. This study presents a machine learning framework for predicting mortality following MI using a publicly available dataset of 1700 patient records, and after excluding records with over 20 missing values and features with more than 300 missing entries, the final dataset included 1547 patients and 113 variables, categorized as binary, categorical, integer, or continuous. Missing values were addressed using denoising autoencoders for continuous features and variational autoencoders for the remaining data. In contrast, feature selection was performed using Random Forest, and PowerTransformer scaling was applied, addressing class imbalance by using SMOTE. Twelve models were evaluated, including Focal-Loss Neural Networks, TabNet, XGBoost, LightGBM, CatBoost, Random Forest, SVM, Logistic Regression, and a voting ensemble. Performance was assessed using multiple metrics, with SVM achieving the highest F1 score (0.6905), ROC-AUC (0.8970), and MCC (0.6464), while Random Forest yielded perfect precision and specificity. To assess generalizability, a subpopulation external validation was conducted by training on male patients and testing on female patients. XGBoost and CatBoost reached the highest ROC-AUC (0.90), while Focal-Loss Neural Network achieved the best MCC (0.53). Overall, the proposed framework outperformed previous studies in key metrics and maintained better performance under demographic shift, supporting its potential for clinical decision-making in post-MI care.